ABUS
NASDAQ · Biotechnology
Arbutus Biopharma Corp
$4.34
-0.07 (-1.59%)
Open$4.40
Previous Close$4.41
Day High$4.45
Day Low$4.27
52W High$5.38
52W Low$3.31
Volume—
Avg Volume1.19M
Market Cap901.76M
P/E Ratio5.61
EPS$0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,080.9% upside
Current
$4.34
$4.34
Target
$51.25
$51.25
$34.47
$51.25 avg
$59.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 15.27M | 21.45M | 146.67M |
| Net Income | -36,319,720 | -45,909,758 | -16,611,843 |
| Profit Margin | -237.9% | -226.0% | -11.3% |
| EBITDA | -40,994,741 | -54,698,039 | -23,689,130 |
| Free Cash Flow | — | — | -19,958,595 |
| Rev Growth | -28.8% | -28.8% | -8.1% |
| Debt/Equity | 0.04 | 0.04 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |